Umbilical cord mesenchymal stem cell transplantation for treatment of experimental autoimmune myasthenia gravis in rats.
- Author:
Jing-Xia YU
1
;
Fang CHEN
;
Jun SUN
;
Ji-Ming WANG
;
Qin-Jun ZHAO
;
Xin-Jun REN
;
Feng-Xia MA
;
Shao-Guang YANG
;
Zhi-Bo HAN
;
Zhong-Chao HAN
Author Information
1. State key Laboratory of Experimental Hematology, Institute of Hematology and Hospital of Blood Diseases, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China.
- Publication Type:Journal Article
- MeSH:
Animals;
Cord Blood Stem Cell Transplantation;
Female;
Humans;
Mesenchymal Stem Cell Transplantation;
Myasthenia Gravis, Autoimmune, Experimental;
therapy;
Rats;
Rats, Inbred Lew
- From:
Journal of Experimental Hematology
2011;19(3):744-748
- CountryChina
- Language:Chinese
-
Abstract:
Umbilical cord mesenchymal stem cell (UCMSC) transplantation has been widely used in the treatment of a variety of diseases due to their advantages such as abundant resources, low immunogenicity and large ex vivo expansion capacity. This study was aimed to investigate the effects of UCMSC on experimental autoimmune myasthenia gravis (EAMG) rats. The distribution of human-derived cells was observed by immunofluorescence method, the effect of MSC on B-cell in situ-secreted antibodies was assayed by ELISPOT, the secreted IFN-γ level was detected by using Transwell test. The results showed that UCMSC were able to migrate to inflammation region and lymph nudes, moreover human-derived cells could be detected in medulla zone of lymph nudes. In vitro in situ detection of AchR specific antibody secretion revealed that the full contact of MSC with lymphnode-derived lymphocytes could effectively inhibit production of AchR antibody. Transwell test indicated that the direct contact of UCMSC with CD4 T cells could effectively decrease production of IFN-γ, which modulated the unbalance between Th1/Th2 to a certain extent. It is concluded that UCMSC can regulate the immune system by direct cell-cell contact or/and release of cytokines, which bring a new insight into knowledge about MSC-based therapy for EAMG.
